14.2 Clinical Trials in Breast Oncology
Key Takeaways
Phase I trials find safe doses, phase II trials look for activity, phase III trials compare a new treatment with the standard of care, and phase IV studies monitor safety after approval.
Informed consent for research is an ongoing process that includes purpose, procedures, risks, benefits, alternatives, confidentiality, and the right to withdraw at any time without penalty.
Institutional review boards oversee research ethics, and adverse events are graded with the NCI Common Terminology Criteria for Adverse Events (CTCAE).
The Affordable Care Act requires most health plans to cover routine patient care costs for people enrolled in approved clinical trials.
Common trial endpoints include overall survival, invasive disease-free survival, progression-free survival, pathologic complete response, and patient-reported outcomes.
Why Trials Matter to Breast Care Nurses
Nearly every standard therapy in this guide, from sentinel node biopsy to CDK4/6 inhibitors, was proven in clinical trials. Nurses identify eligible patients, explain trials, support informed consent, deliver protocol treatment, assess and report adverse events, and advocate for participants.
Trial Phases
Advances in breast cancer survival depend upon rigorous clinical trials. Breast care nurses educate patients regarding trial phases and advocate for equitable participation:
- Phase I Trials: Evaluate the safety profile, determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), assess pharmacokinetics/pharmacodynamics, and identify acute toxicities of a novel agent in small patient cohorts (typically 15 to 30 patients).
- Phase II Trials: Evaluate the preliminary therapeutic efficacy of a drug against specific breast cancer subtypes and further characterize safety and side-effect profiles (typically 50 to 100 patients).
- Phase III Trials: Compare the new investigational therapy against the current established standard-of-care therapy in large, randomized, multicenter patient cohorts (hundreds to thousands of patients) to determine definitive improvements in disease-free survival, progression-free survival, and overall survival.
- Phase IV Trials: Post-marketing surveillance conducted after FDA approval to evaluate long-term safety, rare toxicities, and therapeutic effectiveness in broad, real-world patient populations.
Overcoming Barriers to Participation
Racial and ethnic minorities are historically underrepresented in cancer clinical trials, and Black patients in particular make up a much smaller share of breast cancer trial participants than of people living with the disease. Breast care nurses address trial enrollment barriers by:
- Dismantling Placebo Misconceptions: Clarifying for patients that therapeutic cancer trials never utilize a placebo alone when an effective standard-of-care therapy exists; investigational agents are added to standard therapy or compared directly against standard care.
- Addressing Logistical Hurdles: Working with trial coordinators to arrange transportation, lodging, and flexible visit windows.
- Fostering Trust: Providing culturally sensitive, unhurried education that respects historical community concerns regarding medical exploitation.
Trial Design Basics
- Randomization assigns participants to arms by chance to balance known and unknown factors.
- Blinding keeps participants and/or investigators unaware of assignments to reduce bias; double-blind trials blind both.
- Control arms use the current standard of care. When no effective standard exists, a placebo may be used, but in cancer treatment trials a placebo is usually added to standard therapy (for example, placebo plus endocrine therapy) rather than given alone.
- Phase 0 studies give tiny doses to study drug behavior without therapeutic intent.
Common Endpoints
| Endpoint | Meaning |
|---|---|
| Overall survival (OS) | Time to death from any cause; the gold standard |
| Invasive disease-free survival (iDFS) | Time to invasive recurrence, new invasive cancer, or death; common in adjuvant trials |
| Progression-free survival (PFS) | Time to disease progression or death; common in metastatic trials |
| Pathologic complete response (pCR) | No residual invasive cancer in breast and nodes after neoadjuvant therapy |
| Objective response rate (ORR) | Proportion with tumor shrinkage meeting criteria |
| Patient-reported outcomes (PROs) | Symptoms, function, and quality of life reported by participants |
Informed Consent and Oversight
Federal regulations (the Common Rule and FDA regulations) and Good Clinical Practice require that consent documents and discussions cover the study's purpose and duration, procedures, foreseeable risks and discomforts, possible benefits, alternatives (including standard treatment and no treatment), confidentiality, compensation for injury, whom to contact, and the fact that participation is voluntary and the participant may withdraw at any time without losing benefits or standard care.
Consent is a process, not a signature: information is repeated and updated when new risks emerge (re-consent). Nurses watch for therapeutic misconception, when a participant believes the trial is designed mainly to benefit them personally rather than to answer a scientific question. Institutional review boards (IRBs) approve and monitor studies, and data and safety monitoring boards review accumulating results.
Adverse Event Assessment and Reporting
Adverse events are graded with the NCI Common Terminology Criteria for Adverse Events (CTCAE), from grade 1 (mild) to grade 5 (death). The investigator attributes each event (unrelated to definitely related). Serious adverse events (death, life-threatening events, hospitalization, disability, congenital anomaly) must be reported to the sponsor and IRB within protocol timelines, often 24 hours for initial notice. Accurate, contemporaneous nursing documentation is essential.
Nursing Roles
- Research nurses screen eligibility, coordinate visits, ensure protocol-specified labs and imaging happen on schedule, maintain drug accountability, and document precisely.
- Treating nurses administer investigational agents per protocol, recognize unexpected toxicities, and report deviations.
- All nurses raise awareness of trials, use resources such as ClinicalTrials.gov and NCI cooperative groups (for example, NRG Oncology, SWOG, Alliance, and ECOG-ACRIN) and the NCI Community Oncology Research Program, and protect participants' rights.
Coverage and Access
The Affordable Care Act requires most private plans to cover routine patient care costs for participants in approved trials, and Medicare covers routine costs under its clinical trial policy. Sponsors usually cover the investigational drug and research-only tests. Travel, lodging, and time off work remain barriers that navigators and trial coordinators help address.
Special Protections in Research
Trials exclude or add safeguards for pregnant people, and most require pregnancy testing and effective contraception during and after investigational therapy. Adults who cannot consent need a legally authorized representative, and research use of health information requires a HIPAA authorization. Newer trials may use decentralized elements, such as home nursing visits, local labs, and telehealth consent, which can reduce travel burden but still require the same protections.
When advocating for clinical trial participation to a patient from an underrepresented racial or ethnic background who expresses historical mistrust of medical research, which nursing communication strategy best reflects professional ethics and evidence-based practice?
Pressure the patient into enrolling immediately by stating that refusal will compromise the standard of care provided by the oncology team.
Dismiss the patient's concerns as unfounded because institutional review boards now monitor all clinical research without human error.
Assure the patient that enrolled participants in therapeutic breast oncology trials are always given a placebo sugar pill instead of active therapy.
Acknowledge historical injustices, explore specific concerns, clarify that trial protocols always provide at least the current standard of care as the baseline, and support autonomous shared decision-making.
A patient enrolled in a phase III adjuvant trial tells the nurse she wants to stop participating because the study visits are too burdensome. What is the appropriate response?
Tell her she signed a contract and must complete the study.
Explain that withdrawing will end her access to all cancer care at the center.
Tell her she must pay back the cost of the study drug if she withdraws.
Confirm that she may withdraw at any time without penalty, notify the research team, and ensure she continues to receive standard care.
A new investigational drug has shown activity in phase II. The next trial randomly assigns 1,200 patients to the drug plus standard endocrine therapy or placebo plus standard endocrine therapy, measuring invasive disease-free survival. What type of trial is this?
Phase I
Phase III
Phase IV
Phase 0
Sections you finish are checked off in the contents.